![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, April 08, 2023 6:14:48 PM
What they pretend not to understand, is that crossover renders the comparison against placebo noncrossovers ridiculous, because they nearly all died early (but only include a third of control), and against the entire group because crossover makes the comparison against unimpeded by (pretreated) TMZ DCVax-l, a very high statistical hurdle.
Maybe I am being simplistic but wouldn't it have been better to compare the mPFS and post progression mOS of the entire 92 member "intend to crossover group" (64 crossovers and 29 permanent placebos) with the mPFS and post progression mOS of the ECAs?
This would be a good comparison because all the patients in the ECAs as well as in the "intend to crossover group" received TMZ and all patients progressed. What you can compare is the mPFS and post progression mOS of the ECAs to the mPFS and post progression mOS of the "intend to crossover group". Most likely the mPFS of the 64 crossovers was considerably longer than that of the ECAs as was their post progression mOS. OTOH the 29 permanent placebos most likely had a shorter PFS as well as a shorter post progression mOS than the ECAs but I bet that while the combined group of 92 "intend to crossover group" had a mPFS that was close to that of the ECAs, the mOS of the combined group of 92 "intend to crossover patients" was much longer than the mOS of the ECAs and that would be due to the post progression efficacy of DCVax-L for the group of 64 crossovers.
While I cannot estimate the mPFS of the 92 patient "intend to crossover
group, I am guessing that the mOS of that combined group is around 24 months.
![Bullish](/static/images/ih2-bull.png)
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM